Emerald Health Pharmaceuticals receives fast track designation from US FDA for EHP-101 in the treatment of systemic sclerosis

Emerald Health Pharmaceuticals

3 March 2020 - First-in-class product candidate in Phase 2 clinical development now has fast track and orphan designations.

Emerald Health Pharmaceuticals has been granted fast track designation from the US FDA for its lead clinical-stage product candidate, EHP-101, for the treatment of systemic sclerosis (SSc), a severe form of scleroderma.

EHP is currently initiating a Phase 2 clinical study for systemic sclerosis in Australia, New Zealand and the United States with EHP-101, an oral formulation of a patented, synthetic new chemical entity derived from cannabidiol. EHP previously received orphan drug designation in the US and EU for EHP-101 in the treatment of systemic sclerosis.

Read Emerald Health Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track